Beurs gesloten -
Andere beurzen
|
Variatie 5 dagen | Verschil t.o.v. 1 jan (%) | ||
1,51 USD | -5,62% | -15,17% | -43,45% |
Omzet 2024 * | - | Omzet 2025 * | - | Marktkapitalisatie | 1,99 mln. 1,86 mln. |
---|---|---|---|---|---|
Nettowinst (verlies) 2024 * | -23 mln. -21,51 mln. | Nettowinst (verlies) 2025 * | -26 mln. -24,32 mln. | EV/omzet 2024 * | - |
Nettoliquiditeiten 2024 * | - 0 | Nettoliquiditeiten 2025 * | - 0 | EV/omzet 2025 * | - |
K/w-verhouding 2024 * |
-0,11
x | K/w-verhouding 2025 * |
-0,06
x | Werknemers | 12 |
Dividendrendement 2024 * |
-
| Dividendrendement 2025 * |
-
| Vrij verhandelbaar | 74,05% |
Recentste transcriptie over Cyclacel Pharmaceuticals, Inc.
1 dag | -5,63% | ||
1 week | -15,17% | ||
Lopende maand | -28,43% | ||
1 maand | -21,35% | ||
3 maanden | -28,77% | ||
6 maanden | -81,72% | ||
Lopend jaar | -43,45% |
Managers | Titel | Leeftijd | Van |
---|---|---|---|
Spiro Rombotis
CEO | Chief Executive Officer | 65 | 01-08-97 |
Paul McBarron
DFI | Director of Finance/CFO | 63 | 01-01-02 |
Brian Schwartz
CTO | Chief Tech/Sci/R&D Officer | 52 | 17-12-20 |
Besturend | Titel | Leeftijd | Van |
---|---|---|---|
Chairman | 83 | 01-03-06 | |
Brian Schwartz
CTO | Chief Tech/Sci/R&D Officer | 52 | 17-12-20 |
Spiro Rombotis
CEO | Chief Executive Officer | 65 | 01-08-97 |
Datum | Koers | Variatie | Volume |
---|---|---|---|
26-04-24 | 1,51 | -5,63% | 181 642 |
25-04-24 | 1,6 | -30,43% | 3 489 580 |
24-04-24 | 2,3 | +28,49% | 551 102 |
23-04-24 | 1,79 | +2,29% | 28 374 |
22-04-24 | 1,75 | -1,69% | 25 527 |
uitgestelde koers Nasdaq, 26 april 2024 om 22:30 uur
Meer koersenHerzieningen van WPA
Vaira. 1 jan. | Kapi. | |
---|---|---|
-43,45% | 1,99 mln. | |
-2,31% | 103 mld. | |
+0,56% | 95,28 mld. | |
+1,69% | 22,15 mld. | |
-17,37% | 21,02 mld. | |
-9,30% | 18,15 mld. | |
-41,01% | 16,74 mld. | |
-14,85% | 16,05 mld. | |
+3,21% | 13,68 mld. | |
+33,54% | 12,17 mld. |